{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:08:53Z","timestamp":1792627733640,"version":"4.5.0"},"reference-count":132,"publisher":"Bentham Science Publishers Ltd.","issue":"12","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPB"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Osteoporosis, one of the most prevalent bone illnesses, majorly affects postmenopausal\nwomen and men over 50 years of age. Osteoporosis is associated with an increased\nsusceptibility to fragility fractures and can result in persistent pain and significant impairment in\naffected individuals. The primary method for diagnosing osteoporosis involves the assessment of\nbone mineral density (BMD) through the utilisation of dual energy x-ray absorptiometry\n(DEXA). The integration of a fracture risk assessment algorithm with bone mineral density\n(BMD) has led to significant progress in the diagnosis of osteoporosis. Given that osteoporosis is\na chronic condition and multiple factors play an important role in maintaining bone mass,\ncomprehending its underlying mechanism is crucial for developing more effective pharmaceutical\ninterventions for the disease. The effective management of osteoporosis involves the\nutilisation of appropriate pharmacological agents in conjunction with suitable dietary\ninterventions and lifestyle modifications. This review provides a comprehensive understanding\nof the types of osteoporosis and elucidates the currently available pharmacological treatment\noptions and their related mechanism of action and usage.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0113892010273783231027073117","type":"journal-article","created":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T07:04:16Z","timestamp":1699427056000},"page":"1538-1551","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Insights into the Mechanism of Osteoporosis and the Available Treatment\nOptions"],"prefix":"10.2174","volume":"25","author":[{"given":"Rajeshwari","family":"Muniyasamy","sequence":"first","affiliation":[{"name":"School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inderchand","family":"Manjubala","sequence":"additional","affiliation":[{"name":"School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1001\/jama.285.6.785","volume":"285","author":"Klibanski A.","year":"2001","unstructured":"Klibanski A.; Adams-Campbell L.; Bassford T.; Blair S.N.; Boden S.D.; Dickersin K.; Osteoporosis prevention, diagnosis, and therapy. JAMA  2001,285(6),785-795","journal-title":"JAMA"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.5152\/eurjrheum.2016.048","volume":"4","author":"S\u00f6zen T.","year":"2017","unstructured":"S\u00f6zen T.; \u00d6z\u0131\u015f\u0131k, L.; Calik Basaran, N. An overview and management of osteoporosis. Eur J Rheumatol  2017,4(1),46-56","journal-title":"Eur J Rheumatol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2165\/00024677-200302050-00005","volume":"2","author":"Mahakala A.","year":"2003","unstructured":"Mahakala A.; Thoutreddy S.; Kleerekoper M.; Prevention and treatment of postmenopausal osteoporosis. Treat Endocrinol  2003,2(5),331-345","journal-title":"Treat Endocrinol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1007\/s00198-004-1702-6","volume":"16","author":"Johnell O.","year":"2005","unstructured":"Johnell O.; Kanis J.; Epidemiology of osteoporotic fractures. Osteoporos Int  2005,16(S02),S3-S7","journal-title":"Osteoporos Int"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1055\/s-0038-1660790","volume":"6","author":"Akkawi I.","year":"2018","unstructured":"Akkawi I.; Zmerly H.; Osteoporosis: Current concepts. Joints  2018,6(2),122-127","journal-title":"Joints"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","volume":"17","author":"Johnell O.","year":"2006","unstructured":"Johnell O.; Kanis J.A.; An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int  2006,17(12),1726-1733","journal-title":"Osteoporos Int"},{"key":"ref=7","year":"2006","unstructured":"Key statistic for Asia. International osteoporosis foundation.  Available from: 2006"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.2147\/TCRM.S138000","volume":"14","author":"Pouresmaeili F.","year":"2018","unstructured":"Pouresmaeili F.; Kamali Dehghan B.; Kamarehei M.; Yong Meng G.; A comprehensive overview on osteoporosis and its risk factors. Ther Clin Risk Manag  2018,14,2029-2049","journal-title":"Ther Clin Risk Manag"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1097\/GRF.0b013e3182a9fb02","volume":"56","author":"Pinkerton J.","year":"2013","unstructured":"Pinkerton J.; Thomas S.; Dalkin A.C.; Osteoporosis treatment and prevention for postmenopausal women: Current and future therapeutic options. Clin Obstet Gynecol  2013,56(4),711-721","journal-title":"Clin Obstet Gynecol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s40520-021-01817-y","volume":"33","author":"Barnsley J.","year":"2021","unstructured":"Barnsley J.; Buckland G.; Chan P.E.; Ong A.; Ramos A.S.; Baxter M.; Laskou F.; Dennison E.M.; Cooper C.; Patel H.P.; Pathophysiology and treatment of osteoporosis: Challenges for clinical practice in older people. Aging Clin Exp Res  2021,33(4),759-773","journal-title":"Aging Clin Exp Res"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41584-019-0172-3","volume":"15","author":"Seeman E.","year":"2019","unstructured":"Seeman E.; Martin T.J.; Antiresorptive and anabolic agents in the prevention and reversal of bone fragility. Nat Rev Rheumatol  2019,15(4),225-236","journal-title":"Nat Rev Rheumatol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3389\/fphar.2017.00803","volume":"8","author":"Pavone V.","year":"2017","unstructured":"Pavone V.; Testa G.; Giardina S.M.C.; Vescio A.; Restivo D.A.; Sessa G.; Pharmacological therapy of osteoporosis: A systematic current review of literature. Front Pharmacol  2017,8,803","journal-title":"Front Pharmacol"},{"key":"ref=13","doi-asserted-by":"publisher","DOI":"10.17226\/13050","author":"Del Valle H.","year":"2011","unstructured":"Del Valle H.; Yaktine A.; Taylor C.; Ross A.;  Dietary reference intakes for calcium and vitamin D  2011","journal-title":"Dietary reference intakes for calcium and vitamin D"},{"key":"ref=14","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-54016-0","author":"Sinaki M.","year":"2017","unstructured":"Sinaki M.; Pfeifer M.;  Non-Pharmacological Management of Osteoporosis: Exercise, Nutrition, Fall and Fracture Prevention  2017","journal-title":"Non-Pharmacological Management of Osteoporosis: Exercise, Nutrition, Fall and Fracture Prevention"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"S268","DOI":"10.1093\/geront\/gnw031","volume":"56","author":"Bauman A.","year":"2016","unstructured":"Bauman A.; Merom D.; Bull F.C.; Buchner D.M.; Fiatarone Singh M.A.; Updating the evidence for physical activity: Summative reviews of the epidemiological evidence, prevalence, and interventions to promote \u201cActive Aging\u201d. Gerontologist  2016,56(Suppl. 2),S268-S280","journal-title":"Gerontologist"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"78","DOI":"10.4103\/ijpvm.IJPVM_114_18","volume":"9","author":"Fares A.","year":"2018","unstructured":"Fares A.; Pharmacological and non-pharmacological means for prevention of fractures among elderly. Int J Prev Med  2018,9(1),78","journal-title":"Int J Prev Med"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/164_2019_343","volume":"262","author":"Ansari N.","year":"2019","unstructured":"Ansari N.; Sims N.A.; The cells of bone and their interactions. Handb Exp Pharmacol  2019,262,1-25","journal-title":"Handb Exp Pharmacol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/dvdy.20603","volume":"235","author":"Franz-Odendaal T.A.","year":"2006","unstructured":"Franz-Odendaal T.A.; Hall B.K.; Witten P.E.; Buried alive: How osteoblasts become osteocytes. Dev Dyn  2006,235(1),176-190","journal-title":"Dev Dyn"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1007\/s00198-010-1194-5","volume":"21","author":"Rochefort G.Y.","year":"2010","unstructured":"Rochefort G.Y.; Pallu S.; Benhamou C.L.; Osteocyte: The unrecognized side of bone tissue. Osteoporos Int  2010,21(9),1457-1469","journal-title":"Osteoporos Int"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/421746","volume":"2015","author":"Florencio-Silva R.","year":"2015","unstructured":"Florencio-Silva R.; Sasso G.R.S.; Sasso-Cerri E.; Sim\u00f5es M.J.; Cerri P.S.; Biology of bone tissue: Structure, function, and factors that influence bone cells. BioMed Res Int  2015,2015,1-17","journal-title":"BioMed Res Int"},{"key":"ref=21","first-page":"4","volume":"15","author":"Mohamed A.M.F.S.","year":"2008","unstructured":"Mohamed A.M.F.S.; An overview of bone cells and their regulating factors of differentiation. Malays J Med Sci  2008,15(1),4-12","journal-title":"Malays J Med Sci"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature01658","volume":"423","author":"Boyle W.J.","year":"2003","unstructured":"Boyle W.J.; Simonet W.S.; Lacey D.L.; Osteoclast differentiation and activation. Nature  2003,423(6937),337-342","journal-title":"Nature"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1210\/er.2010-0006","volume":"32","author":"Henriksen K.","year":"2011","unstructured":"Henriksen K.; Bollerslev J.; Everts V.; Karsdal M.A.; Osteoclast activity and subtypes as a function of physiology and pathology--implications for future treatments of osteoporosis. Endocr Rev  2011,32(1),31-63","journal-title":"Endocr Rev"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jsbmb.2013.09.008","volume":"142","author":"Tella S.H.","year":"2014","unstructured":"Tella S.H.; Gallagher J.C.; Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol  2014,142,155-170","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.metabol.2017.10.005","volume":"80","author":"Sebastian A.","year":"2018","unstructured":"Sebastian A.; Loots, GG Genetics of Sost\/SOST in sclerosteosis and van Buchem disease animal models. Metab - Clin. Exp  2018,80,38-47","journal-title":"Exp"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1177\/0954411919857599","volume":"234","author":"Della Corte A.","year":"2020","unstructured":"Della Corte A.; Giorgio I.; Scerrato D.; A review of recent developments in mathematical modeling of bone remodeling. Proc Inst Mech Eng H  2020,234(3),273-281","journal-title":"Proc Inst Mech Eng H"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/B978-0-12-416015-6.00004-6","author":"Allen M.R.","year":"2013","unstructured":"Allen M.R.; Burr D.B.; Bone Modeling and Remodeling. Basic and Applied Bone Biology  2013,75-90","journal-title":"Basic and Applied Bone Biology"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1177\/1759720X16670154","volume":"8","author":"Langdahl B.","year":"2016","unstructured":"Langdahl B.; Ferrari S.; Dempster D.W.; Bone modeling and remodeling: Potential as therapeutic targets for the treatment of osteoporosis. Ther Adv Musculoskelet Dis  2016,8(6),225-235","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1146\/annurev-pathol-011110-130203","volume":"6","author":"Feng X.","year":"2011","unstructured":"Feng X.; McDonald J.M.; Disorders of bone remodeling. Annu Rev Pathol  2011,6(1),121-145","journal-title":"Annu Rev Pathol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.cdtm.2015.02.006","volume":"1","author":"Ji M.X.","year":"2015","unstructured":"Ji M.X.; Yu Q.; Primary osteoporosis in postmenopausal women. Chronic Dis Transl Med  2015,1(1),9-13","journal-title":"Chronic Dis Transl Med"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"932","DOI":"10.3390\/cells10040932","volume":"10","author":"Novais A.","year":"2021","unstructured":"Novais A.; Chatzopoulou E.; Chaussain C.; Gorin C.; The potential of FGF-2 in craniofacial bone tissue engineering: A review. Cells  2021,10,932","journal-title":"Cells"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1359\/jbmr.2002.17.12.2281","volume":"17","author":"Kontulainen S.","year":"2002","unstructured":"Kontulainen S.; Siev\u00e4nen H.; Kannus P.; Pasanen M.; Vuori I.; Effect of long-term impact-loading on mass, size, and estimated strength of humerus and radius of female racquet-sports players: A peripheral quantitative computed tomography study between young and old starters and controls. J Bone Miner Res  2002,17(12),2281-2289","journal-title":"J Bone Miner Res"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3389\/fendo.2017.00046","volume":"8","author":"Sugiyama T.","year":"2017","unstructured":"Sugiyama T.; Oda H.; Osteoporosis therapy: Bone modeling during growth and aging. Front Endocrinol  2017,8,46","journal-title":"Front Endocrinol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1111\/dmcn.13196","volume":"58","author":"Ozel S.","year":"2016","unstructured":"Ozel S.; Switzer L.; Macintosh A.; Fehlings D.; Informing evidence-based clinical practice guidelines for children with cerebral palsy at risk of osteoporosis: An update. Dev Med Child Neurol  2016,58(9),918-923","journal-title":"Dev Med Child Neurol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/206489a0","volume":"206","author":"Hattner R.","year":"1965","unstructured":"Hattner R.; Epker B.N.; Frost H.M.; Suggested sequential mode of control of changes in cell behaviour in adult bone remodelling. Nature  1965,206(4983),489-490","journal-title":"Nature"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0889-8529(02)00058-0","volume":"32","author":"Mora S.","year":"2003","unstructured":"Mora S.; Gilsanz V.; Establishment of peak bone mass. Endocrinol Metab Clin North Am  2003,32(1),39-63","journal-title":"Endocrinol Metab Clin North Am"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"187","DOI":"10.7861\/clinmedicine.14-2-187","volume":"14","author":"Coughlan T.","year":"2014","unstructured":"Coughlan T.; Dockery F.; Osteoporosis and fracture risk in older people. Clin Med  2014,14(2),187-191","journal-title":"Clin Med"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1136\/pmj.78.923.526","volume":"78","author":"Tuck S.P.","year":"2002","unstructured":"Tuck S.P.; Francis R.M.; Osteoporosis. Postgrad Med J  2002,78(923),526-532","journal-title":"Postgrad Med J"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"35","DOI":"10.18773\/austprescr.2016.020","volume":"39","author":"Sheu A.","year":"2016","unstructured":"Sheu A.; Diamond T.; Diagnostic Tests: Bone mineral density: Testing for osteoporosis. Aust Prescr  2016,39(2),35-39","journal-title":"Aust Prescr"},{"key":"ref=40","unstructured":"FRAXA WHO Fracture Risk Assessment Tool World Health Organization Available from:  http:\/\/www.shef.ac.uk\/FRAX\/","journal-title":"FRAXA WHO Fracture Risk Assessment Tool"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11657-017-0324-5","volume":"12","author":"Compston J.","year":"2017","unstructured":"Compston J.; Cooper A.; Cooper C.; Gittoes N.; Gregson C.; Harvey N.; Hope S.; Kanis J.A.; McCloskey E.V.; Poole K.E.S.; Reid D.M.; Selby P.; Thompson F.; Thurston A.; Vine N.; UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos  2017,12(1),43","journal-title":"Arch Osteoporos"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"R131","DOI":"10.1530\/EJE-15-0118","volume":"173","author":"Mirza F.","year":"2015","unstructured":"Mirza F.; Canalis E.; Management of endocrine disease: Secondary osteoporosis: Pathophysiology and management. Eur J Endocrinol  2015,173(3),R131-R151","journal-title":"Eur J Endocrinol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/B978-0-12-373884-4.00059-8","volume":"1","author":"Pacifici R.","year":"2008","unstructured":"Pacifici R.; Mechanisms of estrogen action in bone. Princ Bone Biol Two-Volume Set  2008,1,921-933","journal-title":"Princ Bone Biol Two-Volume Set"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.tem.2012.03.008","volume":"23","author":"Khosla S.","year":"2012","unstructured":"Khosla S.; Oursler M.J.; Monroe D.G.; Estrogen and the skeleton. Trends Endocrinol Metab  2012,23(11),576-581","journal-title":"Trends Endocrinol Metab"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/ijos.2015.57","volume":"8","author":"Zhang D-M","year":"2016","unstructured":"Zhang D-M; Cui D-X; Xu R-S; Zhou Y-C; Zheng L-W; Liu, P Phenotypic research on senile osteoporosis caused by SIRT6 deficiency. Int J Oral Sci  2016,8,84-92","journal-title":"Int J Oral Sci"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3390\/ijms21010349","volume":"21","author":"Qadir A","year":"2020","unstructured":"Qadir A; Liang S; Wu Z; Chen Z; Hu L; Qian A; Senile osteoporosis: The involvement of differentiation and senescence of bone marrow stromal cells. Int J Mol Sci  2020,21(1),349","journal-title":"Int J Mol Sci"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.mcna.2020.06.004","volume":"104","author":"Johnston C.B.","year":"2020","unstructured":"Johnston C.B.; Dagar M.; Osteoporosis in older adults. Med Clin North Am  2020,104(5),873-884","journal-title":"Med Clin North Am"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s10522-017-9732-6","volume":"18","author":"Santos L.","year":"2017","unstructured":"Santos L.; Elliott-Sale K.J.; Sale C.; Exercise and bone health across the lifespan. Biogerontology  2017,18,931-946","journal-title":"Biogerontology"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.ajog.2005.08.047","volume":"194","author":"Lane N.E.","year":"2006","unstructured":"Lane N.E.; Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol  2006,194(2),S3-S11","journal-title":"Am J Obstet Gynecol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s11739-017-1719-4","volume":"12","author":"Minisola S.","year":"2017","unstructured":"Minisola S.; Cipriani C.; Occhiuto M.; Pepe J.; New anabolic therapies for osteoporosis. Intern Emerg Med  2017,12(7),915-921","journal-title":"Intern Emerg Med"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/13697137.2021.1951697","volume":"25","author":"Palacios S.","year":"2022","unstructured":"Palacios S.; Medical treatment of osteoporosis. Climacteric  2022,25(1),43-49","journal-title":"Climacteric"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1210\/js.2018-00118","volume":"2","author":"Haas A.V.","year":"2018","unstructured":"Haas A.V.; LeBoff M.S.; Osteoanabolic agents for osteoporosis. J Endocr Soc  2018,2(8),922-932","journal-title":"J Endocr Soc"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1515\/folmed-2015-0037","volume":"57","author":"Mihaylova L.","year":"2015","unstructured":"Mihaylova L.; Peikova L.; Obreshkova D.; Osteoporosis: Therapeutic options. Folia Med  2015,57(3-4),181-190","journal-title":"Folia Med"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/j.1753-4887.2011.00451.x","volume":"70","author":"Banu J.","year":"2012","unstructured":"Banu J.; Varela E.; Fernandes G.; Alternative therapies for the prevention and treatment of osteoporosis. Nutr Rev  2012,70(1),22-40","journal-title":"Nutr Rev"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.3390\/ijms20092213","volume":"20","author":"Chen L.R.","year":"2019","unstructured":"Chen L.R.; Ko N.Y.; Chen K.H.; Medical treatment for osteoporosis: From molecular to clinical opinions. Int J Mol Sci  2019,20(9),2213","journal-title":"Int J Mol Sci"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.4158\/EP161435.ESGL","volume":"22","author":"Camacho P.M.","year":"2016","unstructured":"Camacho P.M.; Petak S.M.; Binkley N.; Clarke B.L.; Harris S.T.; Hurley D.L.; Kleerekoper M.; Lewiecki E.M.; Miller P.D.; Narula H.S.; Pessah-Pollack R.; Tangpricha V.; Wimalawansa S.J.; Watts N.B.; American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis - 2016--Executive Summary. Endocr Pract  2016,22(9),1111-1118","journal-title":"Endocr Pract"},{"key":"ref=57","first-page":"92","volume":"43","author":"Tu K.N.","year":"2018","unstructured":"Tu K.N.; Lie J.D.; Wan C.K.V.; Cameron M.; Austel A.G.; Nguyen J.K.; Van K.; Hyun D.; Osteoporosis: A review of treatment options. P T  2018,43(2),92-104","journal-title":"P T"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1177\/2040622310374783","volume":"1","author":"Lewiecki E.M.","year":"2010","unstructured":"Lewiecki E.M.; Bisphosphonates for the treatment of osteoporosis: Insights for clinicians. Ther Adv Chronic Dis  2010,1(3),115-128","journal-title":"Ther Adv Chronic Dis"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1210\/jc.2009-1947","volume":"95","author":"Watts N.B.","year":"2010","unstructured":"Watts N.B.; Diab D.L.; Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab  2010,95(4),1555-1565","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/3-540-27376-X_8","volume":"12","author":"Fleisch H.","year":"2017","unstructured":"Fleisch H.; Bisphosphonates in osteoporosis. S Afr Pharm J  2017,12,60-64","journal-title":"S Afr Pharm J"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.rbre.2017.01.001","volume":"57","author":"Caires E.L.P.","year":"2017","unstructured":"Caires E.L.P.; Bezerra M.C.; Junqueira A.F.T de A.; Fontenele S.M de A.; Andrade S.C de A.; d\u2019Alva C.B.; Treatment of postmenopausal osteoporosis: A literature-based algorithm for use in the public health care system. Rev Bras Reumatol Engl Ed;  2017,57(3),254-263","journal-title":"Rev Bras Reumatol Engl Ed;"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa030897","volume":"350","author":"Bone H.G.","year":"2004","unstructured":"Bone H.G.; Hosking D.; Devogelaer J.P.; Tucci J.R.; Emkey R.D.; Tonino R.P.; Rodriguez-Portales J.A.; Downs R.W.; Gupta J.; Santora A.C.; Liberman U.A.; Ten years\u2019 experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med  2004,350(12),1189-1199","journal-title":"N Engl J Med"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"115330","DOI":"10.1016\/j.bone.2020.115330","volume":"136","author":"Compston J.","year":"2020","unstructured":"Compston J.; Practical guidance for the use of bisphosphonates in osteoporosis. Bone  2020,136,115330","journal-title":"Bone"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1359\/JBMR.040325","volume":"19","author":"Chesnut C.H.","year":"2004","unstructured":"Chesnut C.H.; Skag A.; Christiansen C.; Recker R.; Stakkestad J.A.; Hoiseth A.; Felsenberg D.; Huss H.; Gilbride J.; Schimmer R.C.; Delmas P.D.; Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res  2004,19(8),1241-1249","journal-title":"J Bone Miner Res"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1002\/art.21918","volume":"54","author":"Delmas P.D.","year":"2006","unstructured":"Delmas P.D.; Adami S.; Strugala C.; Stakkestad J.A.; Reginster J.Y.; Felsenberg D.; Christiansen C.; Civitelli R.; Drezner M.K.; Recker R.R.; Bolognese M.; Hughes C.; Masanauskaite D.; Ward P.; Sambrook P.; Reid D.M.; Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study. Arthritis Rheum  2006,54(6),1838-1846","journal-title":"Arthritis Rheum"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00198-003-1425-0","volume":"14","author":"Ringe J.D.","year":"2003","unstructured":"Ringe J.D.; Dorst A.; Faber H.; Ibach K.; Sorenson F.; Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: Results from a long-term comparative study. Osteoporos Int  2003,14(10),801-807","journal-title":"Osteoporos Int"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1056\/NEJMcp1513724","volume":"374","author":"Black D.M.","year":"2016","unstructured":"Black D.M.; Rosen C.J.; Postmenopausal osteoporosis. N Engl J Med  2016,374(3),254-262","journal-title":"N Engl J Med"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1002\/jbmr.103","volume":"25","author":"Grey A.","year":"2010","unstructured":"Grey A.; Bolland M.; Wattie D.; Horne A.; Gamble G.; Reid I.R.; Prolonged antiresorptive activity of zoledronate: A randomized, controlled trial. J Bone Miner Res  2010,25(10),2251-2255","journal-title":"J Bone Miner Res"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0025-6196(11)60752-0","volume":"84","author":"Kennel K.A.","year":"2009","unstructured":"Kennel K.A.; Drake M.T.; Adverse effects of bisphosphonates: Implications for osteoporosis management. Mayo Clin Proc  2009,84(7),632-638","journal-title":"Mayo Clin Proc"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","volume":"30","author":"Kanis J.A.","year":"2019","unstructured":"Kanis J.A.; Cooper C.; Rizzoli R.; Reginster J.Y.; European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int  2019,30(1),3-44","journal-title":"Osteoporos Int"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","volume":"22","author":"Khosla S.","year":"2007","unstructured":"Khosla S.; Burr D.; Cauley J.; Dempster D.W.; Ebeling P.R.; Felsenberg D.; Gagel R.F.; Gilsanz V.; Guise T.; Koka S.; McCauley L.K.; McGowan J.; McKee M.D.; Mohla S.; Pendrys D.G.; Raisz L.G.; Ruggiero S.L.; Shafer D.M.; Shum L.; Silverman S.L.; Van Poznak C.H.; Watts N.; Woo S.B.; Shane E.; Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the american society for bone and mineral research. J Bone Miner Res  2007,22(10),1479-1491","journal-title":"J Bone Miner Res"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1056\/NEJMc076132","volume":"356","author":"Cummings S.R.","year":"2007","unstructured":"Cummings S.R.; Schwartz A.V.; Black D.M.; Alendronate and atrial fibrillation. N Engl J Med  2007,356(18),1895-1896","journal-title":"N Engl J Med"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/jpc.13768","volume":"54","author":"Simm P.J.","year":"2018","unstructured":"Simm P.J.; Biggin A.; Zacharin M.R.; Rodda C.P.; Tham E.; Siafarikas A.; Jefferies C.; Hofman P.L.; Jensen D.E.; Woodhead H.; Brown J.; Wheeler B.J.; Brookes D.; Lafferty A.; Munns C.F.; Consensus guidelines on the use of bisphosphonate therapy in children and adolescents. J Paediatr Child Health  2018,54(3),223-233","journal-title":"J Paediatr Child Health"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/jbmr.2708","volume":"31","author":"Adler R.A.","year":"2016","unstructured":"Adler R.A.; El-Hajj Fuleihan G.; Bauer D.C.; Camacho P.M.; Clarke B.L.; Clines G.A.; Compston J.E.; Drake M.T.; Edwards B.J.; Favus M.J.; Greenspan S.L.; McKinney R.; Pignolo R.J.; Sellmeyer D.E.; Managing osteoporosis in patients on long-term bisphosphonate treatment: Report of a task force of the american society for bone and mineral research. J Bone Miner Res  2016,31(1),16-35","journal-title":"J Bone Miner Res"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"185","DOI":"10.5694\/mja16.00568","volume":"205","author":"Milat F.","year":"2016","unstructured":"Milat F.; Ebeling P.R.; Osteoporosis treatment: A missed opportunity. Med J Aust  2016,205(4),185-190","journal-title":"Med J Aust"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s40266-023-01043-3","volume":"40","author":"David P.S.","year":"2023","unstructured":"David P.S.; Sobel T.; Sahni S.; Mehta J.; Kling J.M.; Menopausal hormone therapy in older women: Examining the current balance of evidence. Drugs Aging  2023,40(8),675-683","journal-title":"Drugs Aging"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/GCO.0000000000000858","volume":"35","author":"Shah N.","year":"2023","unstructured":"Shah N.; Ariel D.; The role of menopausal hormone therapy in the prevention and treatment of low bone density in perimenopausal and postmenopausal women. Curr Opin Obstet Gynecol  2023,35(2),141-149","journal-title":"Curr Opin Obstet Gynecol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"m3873","DOI":"10.1136\/bmj.m3873","volume":"371","author":"Vinogradova Y.","year":"2020","unstructured":"Vinogradova Y.; Coupland C.; Hippisley-Cox J.; Use of hormone replacement therapy and risk of breast cancer: Nested case-control studies using the QResearch and CPRD databases. BMJ  2020,371,m3873","journal-title":"BMJ"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"564781","DOI":"10.3389\/fendo.2021.564781","volume":"12","author":"Mehta J.","year":"2021","unstructured":"Mehta J.; Kling J.M.; Manson J.E.; Risks, benefits, and treatment modalities of menopausal hormone therapy: Current concepts. Front Endocrinol  2021,12,564781","journal-title":"Front Endocrinol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2165\/00024677-200403020-00006","volume":"3","author":"Mu\u00f1oz-Torres M.","year":"2004","unstructured":"Mu\u00f1oz-Torres M.; Alonso G.; Raya M.P.; Calcitonin therapy in osteoporosis. Treat Endocrinol  2004,3(2),117-132","journal-title":"Treat Endocrinol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.otoeng.2017.10.002","volume":"68","author":"Pe\u00f1a-Rodr\u00edguez Z.A.","year":"2017","unstructured":"Pe\u00f1a-Rodr\u00edguez Z.A.; Haro-Garc\u00eda M.; Benito-Navarro J.R.; Nasal osteoma and inhaled salmon calcitonin: Coincidence or consequence? Acta Otorrinolaringologica  2017,68(6),366-368","journal-title":"Acta Otorrinolaringologica"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.bone.2012.11.011","volume":"53","author":"Nelson E.R.","year":"2013","unstructured":"Nelson E.R.; Wardell S.E.; McDonnell D.P.; The molecular mechanisms underlying the pharmacological actions of estrogens, SERMs and oxysterols: Implications for the treatment and prevention of osteoporosis. Bone  2013,53(1),42-50","journal-title":"Bone"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"787","DOI":"10.4184\/asj.2016.10.4.787","volume":"10","author":"An K.C.","year":"2016","unstructured":"An K.C.; Selective estrogen receptor modulators. Asian Spine J  2016,10(4),787-791","journal-title":"Asian Spine J"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3109\/13697137.2012.688079","volume":"15","author":"Hadji P.","year":"2012","unstructured":"Hadji P.; The evolution of selective estrogen receptor modulators in osteoporosis therapy. Climacteric  2012,15(6),513-523","journal-title":"Climacteric"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"3444","DOI":"10.1001\/archinte.160.22.3444","volume":"160","author":"Johnston C.C.","year":"2000","unstructured":"Johnston C.C.; Bjarnason N.H.; Cohen F.J.; Shah A.; Lindsay R.; Mitlak B.H.; Huster W.; Draper M.W.; Harper K.D.; Heath H.; Gennari C.; Christiansen C.; Arnaud C.D.; Delmas P.D.; Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: Three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med  2000,160(22),3444-3450","journal-title":"Arch Intern Med"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2147\/CIA.S6083","volume":"5","author":"Gennari L.","year":"2010","unstructured":"Gennari L.; Merlotti D.; Nuti R.; Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: Focus on lasofoxifene. Clin Interv Aging  2010,5,19-29","journal-title":"Clin Interv Aging"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.2147\/TCRM.S3476","volume":"4","author":"Gennari L.","year":"2008","unstructured":"Gennari L.; Merlotti D.; De Paola V.; Martini G.; Nuti R.; Bazedoxifene for the prevention of postmenopausal osteoporosis. Ther Clin Risk Manag  2008,4(6),1229-1242","journal-title":"Ther Clin Risk Manag"},{"key":"ref=88","doi-asserted-by":"publisher","DOI":"10.1016\/C2009-0-02210-7","author":"Orwoll E.S.","year":"2010","unstructured":"Orwoll E.S.; Bilezikian J.P.; Vanderschueren D.;  Osteoporosis in Men  2010","journal-title":"Osteoporosis in Men"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1517\/17425255.2015.1000860","volume":"11","author":"Zaheer S.","year":"2015","unstructured":"Zaheer S.; LeBoff M.; Lewiecki E.M.; Denosumab for the treatment of osteoporosis. Expert Opin Drug Metab Toxicol  2015,11(3),461-470","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"Cummings SR","year":"2009","unstructured":"Cummings SR; Martin JS; McClung MR; Siris ES; Eastell R; Reid IR; Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med  2009,361(8),756-765","journal-title":"N Engl J Med"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3389\/fcell.2020.00325","volume":"8","author":"Zhang N.","year":"2020","unstructured":"Zhang N.; Zhang Z.K.; Yu Y.; Zhuo Z.; Zhang G.; Zhang B.T.; Pros and cons of denosumab treatment for osteoporosis and implication for RANKL aptamer therapy. Front Cell Dev Biol  2020,8,325","journal-title":"Front Cell Dev Biol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/ar797","volume":"5","author":"Lane N.E.","year":"2003","unstructured":"Lane N.E.; Kelman A.; A review of anabolic therapies for osteoporosis. Arthritis Res  2003,5(5),214-222","journal-title":"Arthritis Res"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"8","DOI":"10.11005\/jbm.2014.21.1.8","volume":"21","author":"Martin T.J.","year":"2014","unstructured":"Martin T.J.; Bone biology and anabolic therapies for bone: Current status and future prospects. J Bone Metab  2014,21(1),8-20","journal-title":"J Bone Metab"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1002\/jor.24075","volume":"36","author":"Wojda S.J.","year":"2018","unstructured":"Wojda S.J.; Donahue S.W.; Parathyroid hormone for bone regeneration. J Orthop Res  2018,36(10),2586-2594","journal-title":"J Orthop Res"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"499","DOI":"10.2147\/CIA.S241","volume":"2","year":"2008","unstructured":"Riggs; Redman, C.; Riggs, A. Teriparatide in the management of osteoporosis. Clin Interv Aging  2008,2(4),499-507","journal-title":"Clin Interv Aging"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.bone.2018.07.013","volume":"116","author":"Langdahl B.L.","year":"2018","unstructured":"Langdahl B.L.; Silverman S.; Fujiwara S.; Saag K.; Napoli N.; Soen S.; Enomoto H.; Melby T.E.; Disch D.P.; Marin F.; Krege J.H.; Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies. Bone  2018,116,58-66","journal-title":"Bone"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.bone.2018.10.015","volume":"120","author":"Miller P.D.","year":"2019","unstructured":"Miller P.D.; Hattersley G.; Lau E.; Fitzpatrick L.A.; Harris A.G.; Williams G.C.; Hu M.Y.; Riis B.J.; Russo L.; Christiansen C.; Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial. Bone  2019,120,137-140","journal-title":"Bone"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.bone.2018.10.012","volume":"120","author":"Chandler H.","year":"2019","unstructured":"Chandler H.; Lanske B.; Varela A.; Guillot M.; Boyer M.; Brown J.; Pierce A.; Ominsky M.; Mitlak B.; Baron R.; Kostenuik P.; Hattersley G.; Abaloparatide, a novel osteoanabolic PTHrP analog, increases cortical and trabecular bone mass and architecture in orchiectomized rats by increasing bone formation without increasing bone resorption. Bone  2019,120,148-155","journal-title":"Bone"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1210\/jc.2013-4440","volume":"99","author":"Leder B.Z.","year":"2014","unstructured":"Leder B.Z.; Tsai J.N.; Uihlein A.V.; Burnett-Bowie S.A.M.; Zhu Y.; Foley K.; Lee H.; Neer R.M.; Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): A randomized controlled trial. J Clin Endocrinol Metab  2014,99(5),1694-1700","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1590\/S0004-27302006000400019","volume":"50","author":"Girotra M.","year":"2006","unstructured":"Girotra M.; Rubin M.R.; Bilezikian J.P.; Anabolic skeletal therapy for osteoporosis. Arq Bras Endocrinol Metabol  2006,50(4),745-754","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2147\/ciia.2006.1.4.367","volume":"1","author":"Blake G.M.","year":"2006","unstructured":"Blake G.M.; Fogelman I.; Strontium ranelate: A novel treatment for postmenopausal osteoporosis: A review of safety and efficacy. Clin Interv Aging  2006,1(4),367-375","journal-title":"Clin Interv Aging"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1177\/2042098611411012","volume":"2","author":"McGreevy C.","year":"2011","unstructured":"McGreevy C.; Williams D.; Safety of drugs used in the treatment of osteoporosis. Ther Adv Drug Saf  2011,2(4),159-172","journal-title":"Ther Adv Drug Saf"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1177\/1759720X13483187","volume":"5","author":"Cianferotti L.","year":"2013","unstructured":"Cianferotti L.; D\u2019Asta F.; Brandi M.L.; A review on strontium ranelate long-term antifracture efficacy in the treatment of postmenopausal osteoporosis. Ther Adv Musculoskelet Dis  2013,5(3),127-139","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1210\/jc.2012-3048","volume":"98","author":"Kaufman J.M.","year":"2013","unstructured":"Kaufman J.M.; Audran M.; Bianchi G.; Braga V.; Diaz-Curiel M.; Francis R.M.; Goemaere S.; Josse R.; Palacios S.; Ringe J.D.; Felsenberg D.; Boonen S.; Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men. J Clin Endocrinol Metab  2013,98(2),592-601","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.2147\/DDDT.S127568","volume":"11","author":"Lim S.Y.","year":"2017","unstructured":"Lim S.Y.; Bolster M.; Profile of romosozumab and its potential in the management of osteoporosis. Drug Des Devel Ther  2017,11,1221-1231","journal-title":"Drug Des Devel Ther"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"McClung M.R.","year":"2014","unstructured":"McClung M.R.; Grauer A.; Boonen S.; Bolognese M.A.; Brown J.P.; Diez-Perez A.; Langdahl B.L.; Reginster J-Y.; Zanchetta J.R.; Wasserman S.M.; Katz L.; Maddox J.; Yang Y-C.; Libanati C.; Bone H.G.; Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med  2014,370(5),412-420","journal-title":"N Engl J Med"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","volume":"390","author":"Langdahl B.L.","year":"2017","unstructured":"Langdahl B.L.; Libanati C.; Crittenden D.B.; Bolognese M.A.; Brown J.P.; Daizadeh N.S.; Dokoupilova E.; Engelke K.; Finkelstein J.S.; Genant H.K.; Goemaere S.; Hyldstrup L.; Jodar-Gimeno E.; Keaveny T.M.; Kendler D.; Lakatos P.; Maddox J.; Malouf J.; Massari F.E.; Molina J.F.; Ulla M.R.; Grauer A.; Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: A randomised, open-label, phase 3 trial. Lancet  2017,390(10102),1585-1594","journal-title":"Lancet"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nrrheum.2018.5","volume":"14","author":"Ferrari SL","year":"2018","unstructured":"Ferrari SL; Romosozumab to rebuild the foundations of bone strength. Nat Rev Rheumatol  2018,14,128","journal-title":"Nat Rev Rheumatol"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1007\/s10067-020-04948-1","volume":"39","author":"Kaveh S.","year":"2020","unstructured":"Kaveh S.; Hosseinifard H.; Ghadimi N.; Vojdanian M.; Aryankhesal A.; Efficacy and safety of Romosozumab in treatment for low bone mineral density: A systematic review and meta-analysis. Clin Rheumatol  2020,39(11),3261-3276","journal-title":"Clin Rheumatol"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"607017","DOI":"10.3389\/fphar.2020.607017","volume":"11","author":"Zhang C.","year":"2021","unstructured":"Zhang C.; Song C.; Combination Therapy of PTH and Antiresorptive Drugs on Osteoporosis: A Review of Treatment Alternatives. Front Pharmacol  2021,11,607017","journal-title":"Front Pharmacol"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"e015187","DOI":"10.1136\/bmjopen-2016-015187","volume":"8","author":"Lou S.","year":"2018","unstructured":"Lou S.; Lv H.; Li Z.; Zhang L.; Tang P.; Combination therapy of anabolic agents and bisphosphonates on bone mineral density in patients with osteoporosis: A meta-analysis of randomised controlled trials. BMJ Open  2018,8(3),e015187","journal-title":"BMJ Open"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1210\/jc.2016-1160","volume":"101","author":"Tsai J.N.","year":"2016","unstructured":"Tsai J.N.; Uihlein A.V.; Burnett-Bowie S.M.; Neer R.M.; Derrico N.P.; Lee H.; Bouxsein M.L.; Leder B.Z.; Effects of two years of teriparatide, denosumab, or both on bone microarchitecture and strength (DATA-HRpQCT study). J Clin Endocrinol Metab  2016,101(5),2023-2030","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/jbmr.4161","volume":"36","author":"Ramchand S.K.","year":"2021","unstructured":"Ramchand S.K.; David N.L.; Lee H.; Bruce M.; Bouxsein M.L.; Leder B.Z.; Tsai J.N.; Effects of combination denosumab and HIGH-DOSE teriparatide administration on bone microarchitecture and estimated strength: The DATA-HD HR-PQCT study. J Bone Miner Res  2021,36(1),41-51","journal-title":"J Bone Miner Res"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"16055","DOI":"10.1038\/boneres.2016.55","volume":"5","author":"Nakamura Y.","year":"2017","unstructured":"Nakamura Y.; Suzuki T.; Kamimura M.; Ikegami S.; Murakami K.; Uchiyama S.; Taguchi A.; Kato H.; Two-year clinical outcome of denosumab treatment alone and in combination with teriparatide in Japanese treatment-naive postmenopausal osteoporotic women. Bone Res  2017,5(1),16055","journal-title":"Bone Res"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1210\/jc.2009-1703","volume":"95","author":"Finkelstein J.S.","year":"2010","unstructured":"Finkelstein J.S.; Wyland J.J.; Lee H.; Neer R.M.; Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab  2010,95(4),1838-1845","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1007\/s00198-011-1751-6","volume":"23","author":"Li Y.F.","year":"2012","unstructured":"Li Y.F.; Zhou C.C.; Li J.H.; Luo E.; Zhu S.S.; Feng G.; Hu J.; The effects of combined human parathyroid hormone (1-34) and zoledronic acid treatment on fracture healing in osteoporotic rats. Osteoporos Int  2012,23(4),1463-1474","journal-title":"Osteoporos Int"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.jbspin.2010.02.004","volume":"77","author":"Roux S.","year":"2010","unstructured":"Roux S.; New treatment targets in osteoporosis. Joint Bone Spine  2010,77(3),222-228","journal-title":"Joint Bone Spine"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.maturitas.2015.07.003","volume":"82","author":"I\u00f1iguez-Ariza N.M.","year":"2015","unstructured":"I\u00f1iguez-Ariza N.M.; Clarke B.L.; Bone biology, signaling pathways, and therapeutic targets for osteoporosis. Maturitas  2015,82(2),245-255","journal-title":"Maturitas"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3389\/fcell.2020.00433","volume":"8","author":"Dai R.","year":"2020","unstructured":"Dai R.; Wu Z.; Chu H.Y.; Lu J.; Lyu A.; Liu J.; Zhang G.; Cathepsin K.; The action in and beyond bone. Front Cell Dev Biol  2020,8,433","journal-title":"Front Cell Dev Biol"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07391102.2023.2239955","author":"Muniyasamy R.","year":"2023","unstructured":"Muniyasamy R.; Manjubala I.; Identification of potential sclerostin inhibiting flavonoids from Oroxylum indicum: An in silico approach. J Biomol Struct Dyn  2023,1-12","journal-title":"J Biomol Struct Dyn"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07391102.2023.2249103","volume":"0","author":"Adhish M.","year":"2023","unstructured":"Adhish M.; Manjubala I.; An in-silico approach to the potential modulatory effect of taurine on sclerostin (SOST) and its probable role during osteoporosis. J Biomol Struct Dyn  2023,0,1-16","journal-title":"J Biomol Struct Dyn"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"847387","DOI":"10.3389\/fphar.2022.847387","volume":"13","author":"Jiang H.","year":"2022","unstructured":"Jiang H.; Zhang Z.; Yu Y.; Chu H.Y.; Yu S.; Yao S.; Zhang G.; Zhang B.T.; Drug discovery of DKK1 inhibitors. Front Pharmacol  2022,13,847387","journal-title":"Front Pharmacol"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"e12956","DOI":"10.1111\/cpr.12956","volume":"54","author":"Jiang Y.","year":"2021","unstructured":"Jiang Y.; Zhang P.; Zhang X.; Lv L.; Zhou Y.; Advances in mesenchymal stem cell transplantation for the treatment of osteoporosis. Cell Prolif  2021,54(1),e12956","journal-title":"Cell Prolif"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"120717","DOI":"10.1016\/j.lfs.2022.120717","volume":"306","author":"Rudiansyah M.","year":"2022","unstructured":"Rudiansyah M.; El-Sehrawy A.A.; Ahmad I.; Terefe E.M.; Abdelbasset W.K.; Bokov D.O.; Salazar A.; Rizaev J.A.; Muthanna F.M.S.; Shalaby M.N.; Osteoporosis treatment by mesenchymal stromal\/stem cells and their exosomes: Emphasis on signaling pathways and mechanisms. Life Sci  2022,306,120717","journal-title":"Life Sci"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"665813","DOI":"10.3389\/fcell.2021.665813","volume":"9","author":"Tang G.","year":"2021","unstructured":"Tang G.; Liu Z.; Liu Y.; Yu J.; Wang X.; Tan Z.; Ye X.; Recent trends in the development of bone regenerative biomaterials. Front Cell Dev Biol  2021,9,665813","journal-title":"Front Cell Dev Biol"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1016\/j.actbio.2014.01.004","volume":"10","author":"Arcos D.","year":"2014","unstructured":"Arcos D.; Boccaccini A.R.; Bohner M.; D\u00edez-P\u00e9rez A.; Epple M.; G\u00f3mez-Barrena E.; Herrera A.; Planell J.A.; Rodr\u00edguez-Ma\u00f1as L.; Vallet-Reg\u00ed M.; The relevance of biomaterials to the prevention and treatment of osteoporosis. Acta Biomater  2014,10(5),1793-1805","journal-title":"Acta Biomater"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1021\/acsomega.0c03927","volume":"6","author":"Arkin V.H.","year":"2021","unstructured":"Arkin V.H.; Narendrakumar U.; Madhyastha H.; Manjubala I.; Characterization and in vitro evaluations of injectable calcium phosphate cement doped with magnesium and strontium. ACS Omega  2021,6(4),2477-2486","journal-title":"ACS Omega"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"969843","DOI":"10.3389\/fbioe.2022.969843","volume":"10","year":"2022","unstructured":"v K, A.D.; Ray, S.; Arora, U.; Mitra, S.; Sionkowska, A.; Jaiswal, A.K. Dual drug delivery platforms for bone tissue engineering. Front Bioeng Biotechnol  2022,10,969843","journal-title":"Front Bioeng Biotechnol"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"438","DOI":"10.14336\/AD.2019.0523","volume":"11","author":"Ding K.","year":"2020","unstructured":"Ding K.; Hua F.; Ding W.; Gut microbiome and osteoporosis. Aging Dis  2020,11(2),438-447","journal-title":"Aging Dis"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"Black D.M.","year":"1996","unstructured":"Black D.M.; Cummings S.R.; Karpf D.B.; Cauley J.A.; Thompson D.E.; Nevitt M.C.; Bauer D.C.; Genant H.K.; Haskell W.L.; Marcus R.; Ott S.M.; Torner J.C.; Quandt S.A.; Reiss T.F.; Ensrud K.E.; Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet  1996,348(9041),1535-1541","journal-title":"Lancet"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1056\/NEJM200102013440503","volume":"344","author":"McClung M.R.","year":"2001","unstructured":"McClung M.R.; Geusens P.; Miller P.D.; Zippel H.; Bensen W.G.; Roux C.; Adami S.; Fogelman I.; Diamond T.; Eastell R.; Meunier P.J.; Wasnich R.D.; Greenwald M.; Kaufman J-M.; Chesnut C.H.; Reginster J-Y.; Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med  2001,344(5),333-340","journal-title":"N Engl J Med"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"Black D.M.","year":"2007","unstructured":"Black D.M.; Delmas P.D.; Eastell R.; Reid I.R.; Boonen S.; Cauley J.A.; Cosman F.; Lakatos P.; Leung P.C.; Man Z.; Mautalen C.; Mesenbrink P.; Hu H.; Caminis J.; Tong K.; Rosario-Jansen T.; Krasnow J.; Hue T.F.; Sellmeyer D.; Eriksen E.F.; Cummings S.R.; Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med  2007,356(18),1809-1822","journal-title":"N Engl J Med"}],"container-title":["Current Pharmaceutical Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113892010273783231027073117","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/223062\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113892010273783231027073117","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T07:14:44Z","timestamp":1720163684000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/223062\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":132,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113892010273783231027073117","relation":{},"ISSN":["1389-2010"],"issn-type":[{"value":"1389-2010","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-08-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}